Found: 56
Select item for more details and to access through your institution.
Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 4, p. 792, doi. 10.1002/ajh.27236
- By:
- Publication type:
- Article
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 11, p. 1780, doi. 10.1002/ajh.27070
- By:
- Publication type:
- Article
Performance of IPSS‐M in patients with myelodysplastic syndrome after hypomethylating agent failure.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 10, p. E281, doi. 10.1002/ajh.27043
- By:
- Publication type:
- Article
Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 4, p. E91, doi. 10.1002/ajh.26858
- By:
- Publication type:
- Article
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 12, p. 1599, doi. 10.1002/ajh.26731
- By:
- Publication type:
- Article
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 12, p. 1560, doi. 10.1002/ajh.26724
- By:
- Publication type:
- Article
Prediction of survival with intensive chemotherapy in acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 7, p. 865, doi. 10.1002/ajh.26557
- By:
- Publication type:
- Article
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T) and myelodysplastic syndrome with ring sideroblasts (MDS‐RS).
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 7, p. E246, doi. 10.1002/ajh.26182
- By:
- Publication type:
- Article
The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 2, p. 241, doi. 10.1002/ajh.26047
- By:
- Publication type:
- Article
Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 2, p. E50, doi. 10.1002/ajh.26044
- By:
- Publication type:
- Article
Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3).
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 12, p. E326, doi. 10.1002/ajh.25991
- By:
- Publication type:
- Article
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 11, p. 1399, doi. 10.1002/ajh.25950
- By:
- Publication type:
- Article
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 6, p. 612, doi. 10.1002/ajh.25769
- By:
- Publication type:
- Article
A phase II study of omacetaxine mepesuccinate for patients with higher‐risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 1, p. 74, doi. 10.1002/ajh.25318
- By:
- Publication type:
- Article
Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 1, p. 129, doi. 10.1002/ajh.24930
- By:
- Publication type:
- Article
Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 7, p. 599, doi. 10.1002/ajh.24735
- By:
- Publication type:
- Article
Incidental identification of inv(16)(p13.1q22)/CBFB-MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy.
- Published in:
- Cold Spring Harbor Molecular Case Studies, 2021, v. 7, n. 3, p. 1, doi. 10.1101/mcs.a006084
- By:
- Publication type:
- Article
Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies.
- Published in:
- Clinical Infectious Diseases, 2022, v. 75, n. 9, p. 1503, doi. 10.1093/cid/ciac230
- By:
- Publication type:
- Article
Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2020.582213
- By:
- Publication type:
- Article
MDS-439: A Simplified Three-Marker Panel for Myelodysplastic Syndrome Prognostic Outperforms the Well-Established Revised International Prognostic Scoring Systems (IPSS-R).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S351, doi. 10.1016/S2152-2650(21)01813-9
- By:
- Publication type:
- Article
MDS-090: Phase II Study of the IDH2 Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S339, doi. 10.1016/S2152-2650(21)01791-2
- By:
- Publication type:
- Article
Poster: MDS-439: A Simplified Three-Marker Panel for Myelodysplastic Syndrome Prognostic Outperforms the Well-Established Revised International Prognostic Scoring Systems (IPSS-R).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S229, doi. 10.1016/S2152-2650(21)01442-7
- By:
- Publication type:
- Article
Poster: MDS-090: Phase II Study of the IDH2 Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S226, doi. 10.1016/S2152-2650(21)01427-0
- By:
- Publication type:
- Article
Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 5, p. 338, doi. 10.1016/j.clml.2020.12.025
- By:
- Publication type:
- Article
A Phase II Trial of Low-Dose Hypomethylating Agents in Patients with Low- or Intermediate-1-Risk MDS.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S88, doi. 10.1016/j.clml.2016.07.124
- By:
- Publication type:
- Article
Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00915-6
- By:
- Publication type:
- Article
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 5, p. 1, doi. 10.1038/s41408-021-00487-3
- By:
- Publication type:
- Article
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis.
- Published in:
- 2021
- By:
- Publication type:
- Letter to the Editor
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
- Published in:
- Journal of Hematology & Oncology, 2023, v. 16, n. 1, p. 1, doi. 10.1186/s13045-023-01476-8
- By:
- Publication type:
- Article
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.
- Published in:
- Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01229-z
- By:
- Publication type:
- Article
Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia.
- Published in:
- Current Hematologic Malignancy Reports, 2021, v. 16, n. 5, p. 405, doi. 10.1007/s11899-021-00643-3
- By:
- Publication type:
- Article
Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 7, p. 1017, doi. 10.1002/cncr.34609
- By:
- Publication type:
- Article
A retrospective study of cladribine and low‐dose cytarabine–based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 4, p. 560, doi. 10.1002/cncr.34564
- By:
- Publication type:
- Article
Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 19, p. 3552, doi. 10.1002/cncr.33745
- By:
- Publication type:
- Article
Outcomes in patients with newly diagnosed TP53‐mutated acute myeloid leukemia with or without venetoclax‐based therapy.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 19, p. 3541, doi. 10.1002/cncr.33675
- By:
- Publication type:
- Article
Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 17, p. 3113, doi. 10.1002/cncr.33622
- By:
- Publication type:
- Article
Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome–positive acute lymphoblastic leukemia treated with hyper‐CVAD and dasatinib.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 15, p. 2641, doi. 10.1002/cncr.33539
- By:
- Publication type:
- Article
Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Phase 1/2 study of CPX‐351 for patients with Int‐2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 3, p. 898, doi. 10.1111/bjh.19193
- By:
- Publication type:
- Article
Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
- Published in:
- British Journal of Haematology, 2023, v. 203, n. 4, p. 581, doi. 10.1111/bjh.19060
- By:
- Publication type:
- Article
Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome.
- Published in:
- British Journal of Haematology, 2021, v. 195, n. 3, p. 378, doi. 10.1111/bjh.17689
- By:
- Publication type:
- Article
Hematopoiesis under telomere attrition at the single-cell resolution.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-27206-7
- By:
- Publication type:
- Article
Hematopoiesis under telomere attrition at the single-cell resolution.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-27206-7
- By:
- Publication type:
- Article
Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.
- Published in:
- Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. N.PAG, doi. 10.1186/s13045-020-00964-5
- By:
- Publication type:
- Article
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes.
- Published in:
- 2017
- By:
- Publication type:
- journal article